This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matfin, G. Search for Related Content Social Bookmarking                         What's this?

Aspects of drug development and clinical trials — Part 2

Division of Endocrinology and Diabetes, Department of Medicine, New York University School of Medicine, New York, USA, glennmatfin{at}hotmail.com, Novo Nordisk Inc.,100 College Road West Princeton, New Jersey 08540, USA,

References

• The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.[Free Full Text]
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26 and Diabetes Care 2007; 30:162-72.[Abstract/Free Full Text]
• Matfin G. Biomarkers in clinical trials and drug development: measurement of cardiometabolic risk. Br J Diabetes Vasc Dis 2007;7:101-06.[Abstract/Free Full Text]
• Sonnenberg G., Matfin G., Reinhardt R. Drug treatments for obesity: where are we heading and how do we get there? Br J Diabetes Vasc Dis 2007;7:111-18.[Abstract/Free Full Text]
• Pratley R., Matfin G. Pre-diabetes: clinical relevance and therapeutic approach. Br J Diabetes Vasc Dis 2007;7:120-6.[Abstract/Free Full Text]
• Alberti KG, Zimmet P. The metabolic syndrome: time to reflect. Curr Diabetes Rep 2006;6:259-61.[CrossRef]
• Day C. Metabolic syndrome or What you will: definitions and epidemiology. Diabetes Vasc Dis Res 2007;4:32-8.[CrossRef]
• Wald NJ, Law MR A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.[Abstract/Free Full Text]
• Reddy KS The prevention polypill - much promise, insufficient evidence. complications of diabetes. BMJ 2006;333:475-80. New Engl J Med 2007;356:212.[Free Full Text]
• Marshall SM, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 200633:475-80.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 4, 149-150 (2007)
DOI: 10.1177/14746514070070040201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Matfin, G. Search for Related Content Social Bookmarking                         What's this?